60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION
Mark Sulkowski(Johns Hopkins University), Gerhard Steinmann(Boehringer Ingelheim (Germany)), Tarik Asselah(Inserm), S. Mauss(Center for HIV and Hepatogastroenterology), Hugo Tanno(Hospital Provincial de Rosario), E. Ceasu(Medizinische Hochschule Hannover), Florin Alexandru Căruntu(National Institute of Research and Development for Biological Sciences), Liliana Preoțescu(Virginia Commonwealth University), Fernando Bessone(National University of Rosario), Yakov Datsenko(Boehringer Ingelheim (Germany)), Adrian Streinu‐Cercel(Carol Davila University of Medicine and Pharmacy), B. Leggett(Royal Brisbane and Women's Hospital), Jerry O. Stern(Boehringer Ingelheim (United States)), Péter Ferenci(Medical University of Vienna), Hugo Fainboim(Hospital Muñiz), Charles D. Hafner(Heidelberg University), Jacob Lalezari(Quest Clinical Research (United States)), W.O. Böcher(Boehringer Ingelheim (Germany)), Gerhard Nehmiz(Boehringer Ingelheim (Germany))
Cited by 39
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients
|Journal of the American College of Cardiology|2013|826